AMPH vs RDY vs ELTP Stock Comparison

Amphastar Pharmaceuticals, Dr Reddys Laboratories and Elite Pharmaceuticals Prices as of Nov 13, 2026 Peers: Industry group

Head to Head

11 decided of 12

Elite Pharmaceuticals leads on 7 of the 12 questions below (Elite Pharmaceuticals 7, Dr Reddys Laboratories 2, Amphastar Pharmaceuticals 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionAMPHRDYELTPLeader
Larger companyMarket capitalisation $1.25B $12.25B $384.54M RDY
Cheaper on earningsLower P/E, profitable companies only 12.6x 33.7x 6.4x ELTP
Cheaper on forward earningsLower price / next fiscal year consensus EPS 8.8x 30.7x — AMPH
Faster revenue growthRevenue growth, trailing twelve months +3.1% -10.5% +17.8% ELTP
More profitableNet margin, trailing twelve months 13.3% 10.2% 41.6% ELTP
Better return on capitalReturn on invested capital 7.6% 5.6% 27.6% ELTP
Less leveragedLower net debt / EBITDA 7.5x 1.2x -0.9x ELTP
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +11.4% +6.3% -50.7% AMPH
Better 5-year returnAnnualised price return, 5 years +6.6%/yr +2.5%/yr +52.6%/yr ELTP
Less volatileAnnualised volatility, 1 year 53.3% 26.6% 66.6% RDY
Higher overall scoreMean of the five percentile scores vs peers 72/100 57/100 88/100 ELTP

Percentile Scorecard

AMPHRDYELTP

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAMPHRDYELTP
Valuation 98 #13 of 660 90 #66 of 660 94 #40 of 660
Growth 41 #366 of 619 12 #546 of 619 85 #96 of 619
Profitability 87 #78 of 595 85 #92 of 595 91 #52 of 595
Financial Health 35 #443 of 683 41 #405 of 683 81 #130 of 683
Shareholder Returns 98 #12 of 459 60 #186 of 459 87 #63 of 459
Overall 72 57 88
  • AMPH ranked among 695 companies in Pharmaceuticals and Biotechnology
  • RDY ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ELTP ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAMPHRDYELTPSPY
1 month +12.6%+15.7%+32.0% -2.0%
3 months +40.5%+20.1%+6.5% -2.8%
6 months +74.1%+8.4%-5.7% +2.0%
Year to date +9.7%+5.1%-32.7% +10.6%
1 year +11.4%+6.3%-50.7% +12.2%
3 years -47.8%+13.0%+175.0% +68.1%
3 years, per year -19.5%+4.2%+40.1% +18.9%
5 years +37.9%+13.4%+725.0% +61.4%
5 years, per year +6.6%+2.5%+52.6% +10.1%
10 years +40.3%+52.0%+120.0% +248.5%
10 years, per year +3.4%+4.3%+8.2% +13.3%

Risk

MeasureAMPHRDYELTPSPY
Volatility, 1Y 53.3%26.6%66.6% 13.6%
Downside volatility, 1Y 66.0%27.6%72.9% 13.9%
Beta vs S&P 500, 1Y 0.430.340.58 1.00
Return / volatility, 1Y 0.210.24-0.76 0.90
Max drawdown, 5Y -74.0%-32.3%-71.4% -25.4%
From 52-week high -0.1%-4.1%-51.5% -3.2%
52-week high $29.40$15.38$0.68 $779.14
52-week low $16.87$11.40$0.22 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAMPHRDYELTP
P/E now vs peer median 12.6xmedian 17.0x 33.8xmedian 17.0x 5.9xmedian 17.0x
P/S now vs peer median 1.7xmedian 8.4x 3.5xmedian 8.4x 2.5xmedian 8.4x
EV/EBITDA now vs peer median 32.2xmedian 14.6x 24.4xmedian 14.6x 8.4xmedian 14.6x
P/FCF now vs peer median 9.0xmedian 19.0x 882.1xmedian 19.0x 40.8xmedian 19.0x
P/B now vs peer median 1.5xmedian 2.0x 3.0xmedian 2.0x 2.9xmedian 2.0x
PEG now vs peer median -4.05median 0.43 -1.59median 0.43 0.13median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAMPHRDYELTP
Revenue $745.79M $174.86B $144.77M
Gross profit $349.09M $86.67B $63.22M
Operating income $139.74M $16.77B $36.65M
Net income $98.96M $275.07M $60.28M
Free cash flow $139.02M $400.42M $8.72M
R&D $92.29M $12.52B $6.59M
EPS (diluted) $2.28 $0.44 $0.05
Cash & equivalents $204.59M $138.41M $35.34M
Total debt $613.00M $783.69M $2.35M
Shares (diluted) 43.38M 833.33M 1.12B
Enterprise value $151.62M $11.59B $257.95M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAMPHRDYELTP
P/E 12.6x 33.8x 5.9x
P/FCF 9.0x 882.1x 40.8x
P/Operating cash flow 7.1x 36.2x 32.7x
P/S 1.7x 3.5x 2.5x
P/B 1.5x 3.0x 2.9x
P/Tangible book 1.6x 4.1x 3.0x
EV/EBITDA 32.2x 24.4x 8.4x
EV/EBIT 11.7x 37.2x 8.8x
EV/Revenue 2.2x 3.6x 2.2x
EV/FCF 11.8x 926.1x 37.0x
EV/Operating cash flow 9.3x 38.0x 29.7x
PEG (3Y EPS CAGR) -4.05 -1.59 0.13

Growth

14 metrics
MetricAMPHRDYELTP
Revenue growth (1Y) 3.1% -10.5% 17.8%
Revenue CAGR (3Y) 7.4% 3.2% 52.2%
Gross profit growth (1Y) -2.2% -21.5% -2.3%
Gross profit CAGR (3Y) 2.3% -2.3% 47.9%
Operating income growth (1Y) -6.8% -58.2% -13.1%
Operating income CAGR (3Y) -8.2% -24.1% 93.0%
Net income growth (1Y) -11.3% -55.9% 333.0%
Net income CAGR (3Y) -9.9% -21.5% 50.1%
EPS growth (1Y) -2.6% -54.1% 339.9%
EPS CAGR (3Y) -3.1% -21.3% 45.8%
Operating cash flow growth (1Y) 15.1% -39.6% -52.2%
Operating cash flow CAGR (3Y) 0.1% -27.1% 179.9%
Free cash flow growth (1Y) 22.7% -98.4% -59.7%
Free cash flow CAGR (3Y) -0.2% -73.6% 115.9%

Profitability

14 metrics
MetricAMPHRDYELTP
Gross margin 46.8% 49.5% 43.7%
EBITDA margin 6.8% 14.9% 26.4%
Operating margin 18.7% 9.7% 25.3%
Pretax margin 17.4% 10.7% 47.8%
Net margin 13.3% 10.2% 41.6%
FCF margin 18.6% 0.4% 6.0%
Operating cash flow margin 23.5% 9.5% 7.5%
Return on equity 12.5% 7.4% 53.1%
Return on assets 5.7% 5.0% 42.5%
Return on invested capital 7.6% 5.6% 27.6%
Return on capital employed 9.0% 7.9% 29.6%
Asset turnover 0.4x 0.6x 1.0x
Cash conversion (OCF / net income) 1.8x 1.1x 0.2x
Stock comp / revenue 4.0% 0.1% 0.1%

Financial Health

11 metrics
MetricAMPHRDYELTP
Debt / assets 35.8% 12.6% 1.6%
Debt / equity 0.8x 0.2x 0.0x
Net debt / EBITDA 7.5x 1.2x -0.9x
Debt / FCF 4.4x 53.9x 0.3x
Liabilities / assets 52.4% 32.2% 15.3%
Equity / assets 47.6% 67.8% 84.7%
Interest coverage 5.3x 7.2x 46.9x
Current ratio 3.3x 1.9x 6.7x
Quick ratio 2.3x 0.7x 5.4x
Cash ratio 1.3x 0.1x 1.9x
Altman Z-score 2.44 5.79 11.82

Shareholder Returns

7 metrics
MetricAMPHRDYELTP
Dividend yield – 0.5% –
Net buyback yield 7.2% -0.1% 0.0%
Shareholder yield 7.2% 0.5% 0.0%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAMPHRDYELTP
Forward P/E 8.8xFY2026 30.7xFY2026 –
EPS, next fiscal year $3.34FY2026 $0.48FY2026 –
EPS growth, next FY +2.8%FY2026 -11.1%FY2026 –
EPS growth, the year after +6.9% +20.8% –
Revenue, next fiscal year $802.03MFY2026 $3.84BFY2026 –
Revenue growth, next FY +11.4%FY2026 +9.3%FY2026 –
Revenue growth, the year after -5.7% +3.6% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAMPHRDYELTP
Held by institutions 64.8% 15.1% 0.0%
Institutions holding 209 239 1
Change in shares held, QoQ -11.7% +4.3% –
Institutions buying 96 108 1
Institutions selling 74 97 0
Buyers to sellers 1.30 1.11 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

AMPHRDYELTP
AMPH 1.00 0.24 -0.03
RDY 0.24 1.00 0.01
ELTP -0.03 0.01 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, AMPH, RDY and ELTP?

Dr Reddys Laboratories (RDY) is the largest by market capitalisation: Amphastar Pharmaceuticals (AMPH) $1.25B, Dr Reddys Laboratories (RDY) $12.25B, Elite Pharmaceuticals (ELTP) $384.54M.

Which stock is cheaper, AMPH, RDY and ELTP?

Elite Pharmaceuticals (ELTP) trades on the lowest price-to-earnings ratio (Amphastar Pharmaceuticals (AMPH) 12.6x, Dr Reddys Laboratories (RDY) 33.7x, Elite Pharmaceuticals (ELTP) 6.4x). On next year's consensus earnings, Amphastar Pharmaceuticals (AMPH) is cheapest (Amphastar Pharmaceuticals (AMPH) 8.8x, Dr Reddys Laboratories (RDY) 30.7x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Elite Pharmaceuticals (ELTP) grew revenue fastest over the trailing twelve months: Amphastar Pharmaceuticals (AMPH) +3.1%, Dr Reddys Laboratories (RDY) -10.5%, Elite Pharmaceuticals (ELTP) +17.8%.

Which company is more profitable?

Elite Pharmaceuticals (ELTP) has the highest net margin (Amphastar Pharmaceuticals (AMPH) 13.3%, Dr Reddys Laboratories (RDY) 10.2%, Elite Pharmaceuticals (ELTP) 41.6%). On return on invested capital, Elite Pharmaceuticals (ELTP) leads (Amphastar Pharmaceuticals (AMPH) 7.6%, Dr Reddys Laboratories (RDY) 5.6%, Elite Pharmaceuticals (ELTP) 27.6%).

Which stock has performed better?

Over the past year Amphastar Pharmaceuticals (AMPH) returned the most: Amphastar Pharmaceuticals (AMPH) +11.4%, Dr Reddys Laboratories (RDY) +6.3%, Elite Pharmaceuticals (ELTP) -50.7%. Over five years, Elite Pharmaceuticals (ELTP) compounded fastest (Amphastar Pharmaceuticals (AMPH) +6.6%/yr, Dr Reddys Laboratories (RDY) +2.5%/yr, Elite Pharmaceuticals (ELTP) +52.6%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Dr Reddys Laboratories (RDY) has been the steadiest (Amphastar Pharmaceuticals (AMPH) 53.3%, Dr Reddys Laboratories (RDY) 26.6%, Elite Pharmaceuticals (ELTP) 66.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, AMPH, RDY and ELTP?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Elite Pharmaceuticals (ELTP) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.